#USA #Class Action #Philadelphia #Berger Montague #Spectrum Pharmaceuticals

Class Action Alert: Spectrum Pharmaceuticals Under Scrutiny

In recent developments, the prominent law firm Berger Montague PC is actively investigating potential securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). This comes as investors who acquired shares during the designated class period - from March 17, 2022, to September 22, 2022 - are being urged to act swiftly. The deadline for potential participants to seek the role of lead plaintiff is set for September 24, 2025.

Background on the Class Action

The allegations concerning Spectrum Pharmaceuticals center on misleading statements regarding their Pinnacle Study, a clinical trial for the drug poziotinib, designed to treat specific lung cancer patients. Investors who feel that they may have been misled into purchasing or holding stock due to these false representations should consider their options for legal recourse.

After the company announced the results of the clinical trial, which did not meet expectations, Spectrum’s stock faced a significant decline, leading to its eventual delisting post-merger with Assertio Holdings, Inc. (NASDAQ: ASRT).

Who Should Consider Joining the Class Action?

If you are among those who purchased or acquired Spectrum securities within the specified period, now is the time to understand your rights. Berger Montague encourages investors to consider whether they want to join as a lead plaintiff representative for the entire class. Taking this action can provide you with a path to possibly recover financial losses stemming from this alleged fraud.

Contact Information for Investors

For those interested in pursuing this matter further, Berger Montague provides multiple avenues to get involved. Investors can reach out to:

• - Andrew Abramowitz: Senior Counsel - [email protected], (215) 875-3015
• - Caitlin Adorni: [email protected], (267) 764-4865

By reaching out, you can gain invaluable insights into your rights as an investor and what steps to take next.

About Berger Montague

Founded in 1970, Berger Montague has established itself as a leader in securities class action litigation, representing both individual and institutional investors. The firm, with offices across several major cities in the United States, possesses over five decades of experience in advocating for investors' rights. It aims to continue its legacy of serving either as lead or co-lead counsel in high-stakes securities litigation cases throughout the nation.

Final Thoughts

The class action against Spectrum Pharmaceuticals presents a critical opportunity for investors adversely affected by the company’s misrepresentation to seek justice and potential compensation. As the September 24, 2025 deadline approaches, it is essential for affected individuals to act quickly to protect their financial interests.

For more information on your legal options, do not hesitate to contact Berger Montague. Taking proactive steps is crucial in these circumstances, especially as the landscape of securities litigation continues to evolve.